Relevance of Circulating Nucleosomes, HMGB1 and sRAGE for Prostate Cancer Diagnosis

• Type: Article in International Scientific Journal
• Date: 2021

Authors

Garrido, MM (Author) Other; Ribeiro, RM (Author) Other; Kruger, K (Author) Other; Pinheiro, LC (Author) Other; guimaraes, jt (Author) FMUP; Holdenrieder, S (Author) Other

Journal

Title: In Vivo

Vol. 35

Pages: 2207-2212

ISSN: 0258-851X

Publisher: International Institute of Anticancer Research

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 0 Citations

Other information

Authenticus ID: P-00V-WXA

DOI: 10.21873/invivo.12492

Abstract (EN): Background/Aim: Evasion from cell death occurs in prostate cancer (PCa). We verified whether serum levels of cell death markers can have diagnostic value in PCa. Patients and Methods: A total of 233 men scheduled for prostate biopsy [prostate specific antigen (PSA) level: 2-10 ng/ml] were enrolled. Serum nucleosomes, nucleosomes containing the H3 histone (H3), high mobility group box 1 (HMGB1), and soluble receptor for advanced glycation end products (sRAGE) were analyzed by enzyme immunoassays. Results: There were no differences (p>0.05) in nucleosomes, H3, and sRAGE levels between patients with and without PCa or clinically significant PCa (csPCa). HMGB1 had lower levels in PCa patients (p=0.023) and was a predictor of PCa (p=0.047), but not of csPCa (p=0.180). Conclusion: In patients with critical PSA levels between 2-10 ng/ml, HMGB1 had some diagnostic value for overall PCa detection, but it was not predictive of csPCa. Nucleosomes, H3 and sRAGE did not discriminate between PCa or csPCa and controls.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 6